Condition: NSCLC · Sponsor: Regeneron Pharmaceuticals
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Withdrawn |
| University of California Irvine Medical Center - Bldg 56, RT81, Rm 241 | Orange, California, United States | Completed |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Completed |
| Moffitt Cancer Center - McKinley Drive | Tampa, Florida, United States | Recruiting |
| University of Kentucky, Markey Cancer Center Clinical Research Organization | Lexington, Kentucky, United States | Withdrawn |
| DNU_Massachusetts General Hospital_DNU | Boston, Massachusetts, United States | Withdrawn |
| Dana Farber Harvard Cancer Center Consortium | Boston, Massachusetts, United States | Completed |
| Henry Ford Health System | Detroit, Michigan, United States | Withdrawn |
| Washington University School of Medicine | St Louis, Missouri, United States | Withdrawn |
| NYU Cancer Institute | New York, New York, United States | Withdrawn |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Completed |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Completed |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04077099